| 3.045 -0.055 (-1.77%) | 07-26 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
The company is dedicated to creating innovative therapeutic solutions for pressing medical requirements within neurotology and central nervous system disorders. Based in Zug, Switzerland, the firm operates with a modest team of 11 full-time employees. A significant part of its developmental pipeline focuses on intranasal betahistine, specifically AM-125 for addressing vertigo and AM-201 for mitigating antipsychotic-induced weight gain and somnolence. Both betahistine programs are currently in their initial Phase 1 clinical trial stage. Beyond these, the company's product portfolio includes several other promising candidates. Among them are AM-111, a brimapitide-based compound targeting acute inner ear hearing loss, and Keyzilen (AM-101), an eskatemine-based treatment for acute inner ear tinnitus; both are advanced to Phase 3 clinical trials. Additionally, AM-102, another potential treatment for tinnitus, is undergoing preclinical evaluation aimed at identifying the optimal lead compound. The company maintains its operational presence through subsidiary entities located in Switzerland, Ireland, and the United States.
Thu, 24 Apr 2025
Altamira Therapeutics Ltd. (CYTO) Stock Price, News & Analysis - Stock Titan
Tue, 31 Dec 2024
CYTOF - OTC Markets
Fri, 20 Dec 2024
Altamira Therapeutics (OTCPK:CYTO.F) - Stock Analysis - Simply Wall St
Fri, 20 Dec 2024
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets - Yahoo Finance
Mon, 07 Nov 2022
Hearing Loss Disease Treatment Market Report, 2025-2030 - Grand View Research
Thu, 03 Jun 2021
Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|